Wakunaga Pharmaceutical

Wakunaga Pharmaceutical is a long-established, privately-held Japanese company specializing in OTC pharmaceuticals and health supplements derived from aged garlic extract. Its global strategy is centered on its 'Kyolic' brand, which holds a top market share in the U.S. garlic supplement market and has achieved pharmaceutical approval in Germany for atherosclerosis prevention. The company's business model integrates R&D, manufacturing, and direct-to-consumer marketing through expert counseling, with a mission to contribute to global health and longevity.

Proprietary processing and standardization of Aged Garlic Extract (AGE), involving controlled, long-term aging to create stable, bioactive compounds like S-allyl cysteine (SAC). The platform encompasses organic cultivation, extraction, clinical research, and formulation science.

Wakunaga competes in the crowded global dietary supplement and OTC pharmaceutical market. Its primary competition includes other branded garlic supplements and broad-spectrum wellness brands. Its key differentiators are its proprietary aged garlic extract technology, significant scientific backing, pharmaceutical-grade manufacturing, and established trust through decades of market presence, particularly its top share in the U.S. garlic supplement segment.